Kos Pharmaceuticals
Recent News About Kos Pharmaceuticals View More
-
Not all class standards met in pay-for-delay case over cholesterol drug Niaspan, judge finds
PHILADELPHIA – A federal court in Philadelphia recently decided that end-payor plaintiffs (EPPs) failed to meet all qualifications for their putative class, in lawsuits claiming drug companies conspired in a pay-for-delay scheme over cholesterol treatment drug Niaspan.